Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 3/20 | 0.43 |
| ▸ | TACR1 | P25103 | 4/20 | 0.39 |
| ▸ | ACACA | Q13085 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 2/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18909752 | 0.91 | ACACB (0.42) | ACACBTACR1ACACAKDM4EPDE4A | |
| SCHEMBL18820768 | 0.89 | ACACB (0.46) | ACACBTACR1ACACAKDM4EPDE4A | |
| SCHEMBL18820315 | 0.89 | ACACB (0.46) | ACACBTACR1ACACAKDM4EPDE4A | |
| SCHEMBL18908180 | 0.88 | ACACB (0.42) | ACACBTACR1ACACAKDM4EPDE4A | |
| SCHEMBL19361570 | 0.86 | CACNB4 (0.36) | ACACBACACAPDE4APDE4BPDE4C | |
| SCHEMBL18908167 | 0.84 | ACACB (0.49) | ACACBACACAPDE4APDE4BPDE4C | |
| SCHEMBL18914372 | 0.84 | ACACB (0.42) | ACACBACACASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL18821278 | 0.83 | ACACB (0.43) | ACACBTACR1ACACAPDE4APDE4B | |
| SCHEMBL18820854 | 0.78 | ACACA (0.37) | ACACBACACA | |
| SCHEMBL18959743 | 0.76 | ACACB (0.38) | ACACBTACR1ACACASLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170166582-A1 | PYRAZOLE ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. | 2017-06-15 | — | — | US | disclosed |
| US-20170166583-A1 | ESTER ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. | 2017-06-15 | — | — | US | disclosed |
| US-20170166584-A1 | TRIAZOLE ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166583-A1 | ESTER ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | ACACB 2/4885TACR1 4110/4885ACACA 1/4885 |
| US-20170166582-A1 | PYRAZOLE ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, PC | ACACB 2/4885TACR1 4258/4885ACACA 1/4885 |
| US-20170166584-A1 | TRIAZOLE ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT1 | ACACB 2/4885TACR1 3985/4885ACACA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.